Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities

First Phase I study underway in Europe for mRNA 1440; IND for second program, mRNA 1851, filed with the U.S. FDA

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });

Ecosystem of ventures and partners saw significant growth in 2015, propelling rapid expansion of pipeline spanning multiple mRNA-based drug modalities and therapeutic areas

2016 goals focused on advancing multiple clinical trials, fueling continuing early exploration of mRNA modalities and extending investment in core mRNA platform and ventures

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced it is now a clinical stage company with its first Phase I study for mRNA 1440 currently underway in Europe. Moderna also announced it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for mRNA 1851, its second clinical program, with a Phase I study anticipated to begin in Q1 2016. mRNA 1440 and mRNA 1851 are infectious disease vaccines for undisclosed targets and indications. Moderna's Chief Executive Officer, Stéphane Bancel, made the announcement during a presentation today at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, Calif. Mr. Bancel highlighted the company's broad accomplishments in 2015 and outlined key focus areas for 2016.